Insider selling
Traded Dec 10, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Incyte's & Chief Scientific Officer sold $531K of Incyte shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 10, 2025 · Filed Nov 12, 2025
An Incyte director sold $19.8M of Incyte shares. The filing references vesting of compensation awards.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$19,773,750
Shares × reported transaction price
13 days after results of Oct 28, 2025, 92 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $105.98 on Nov 10, 2025, at its 52-week high, after a 26% rise over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $105.98 (Nov 7, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $83.89 on Sep 29, 2025. Describes the past only, not a forecast
RSI 80, 44% above its 200-day average, 19% above its 50-day average, at the 52-week high, 20-day volatility 35% a year, against the S&P 500: +22 points over 1 month, +24 points over 3 months, +57 points over 6 months
From the adjusted closes up to Nov 10, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Herve Hoppenot's largest sale of INCY in their filings since 2017. Herve Hoppenot's first sale of INCY since Jul 2020
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.5% | −2.9% | −0.6% |
| 30 days | −6.4% | +1.3% | −7.7% |
| 90 days | −6.2% | +3.0% | −9.2% |
| 180 days | −6.0% | +9.8% | −15.8% |
| 365 days | +14.8% | +12.3% | +2.5% |
Past results only. Not a forecast.
Insider selling
Traded Dec 10, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Incyte's & Chief Scientific Officer sold $531K of Incyte shares. The filing does not indicate a pre-arranged trading plan.
Patrick A Mayes (EVP & Chief Scientific Officer) sold ~$24K of Incyte
Automatic saleInsider filing
Traded Dec 8, 2025 · filed 2 days later
Routine share withholding; mechanical by default.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.